Octapharma USA
Octapharma USA, Inc.
121 River Street, Suite 1201
Hoboken, NJ 07030
Phone: (201) 604-1130Website: https://www.octapharmausa.com/
Latest news
- FDA Approves Balfaxar (prothrombin complex concentrate, human-lans) for Warfarin Reversal in Urgent Surgery & Invasive Procedures
26 July 2023 - FDA Approves Octapharma’s Octagam 10% for Adult Dermatomyositis
20 July 2021 - FDA Approves Nuwiq (Antihemophilic Factor [Recombinant]) for Hemophilia A
15 September 2015 - Octapharma USA Announces FDA Approval of Octagam 10% for the treatment of Chronic Immune Thrombocytopenic Purpura (ITP)
17 July 2014 - FDA Approves Octagam 5% for the for the Treatment of Primary Immunodeficiency Diseases
24 May 2004
Drugs Associated with Octapharma USA, Inc.
Octapharma USA, Inc. manufactures, markets and/or distributes more than 9 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
albumin human
Generic Drug class: plasma expanders |
||
|
Balfaxar
Generic name: prothrombin complex Drug class: anticoagulant reversal agents |
||
|
Cutaquig
Generic name: immune globulin subcutaneous Drug class: immune globulins |
||
|
Fibryga
Generic name: fibrinogen Drug class: miscellaneous coagulation modifiers |
||
|
Nuwiq
Generic name: antihemophilic factor Drug class: miscellaneous coagulation modifiers |
1 review | 8.0 / 10 |
|
Octagam
Generic name: immune globulin intravenous Drug class: immune globulins |
3 reviews | 8.3 / 10 |
|
Octaplas
Generic name: plasma protein fraction Drug class: plasma expanders |
||
|
Panzyga
Generic name: immune globulin intravenous Drug class: immune globulins |
1 review | 8.0 / 10 |
|
Wilate
Generic name: antihemophilic factor/von willebrand factor Drug class: miscellaneous coagulation modifiers |
1 review | 10 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
